Banco Bilbao Vizcaya Argentaria S.A. Buys 456,583 Shares of Pfizer Inc. $PFE

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Banco Bilbao Vizcaya Argentaria S.A. grew its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 36.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,710,339 shares of the biopharmaceutical company's stock after purchasing an additional 456,583 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Pfizer were worth $43,264,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter worth $27,000. Gould Capital LLC raised its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter worth $27,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter worth $28,000. Finally, Bayforest Capital Ltd bought a new position in shares of Pfizer in the 1st quarter worth about $28,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.07 on Tuesday. The firm's 50-day moving average price is $24.62 and its 200-day moving average price is $24.41. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $142.54 billion, a PE ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research reports. TD Cowen decreased their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. The Goldman Sachs Group increased their price target on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Bank of America increased their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. UBS Group increased their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Leerink Partners decreased their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.